Ollin Biosciences, founded in 2023 and based in Austin, Texas, is advancing a pipeline of bispecific antibodies for retinal and orbital diseases. Its lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody discovered in collaboration with Innovent Biologics; in a 164-patient randomized head-to-head Phase 1b (JADE) study versus faricimab (Vabysmo®) OLN324 demonstrated faster and greater anatomic retinal drying and numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026 after completing regulatory discussions with the FDA and receiving EMA scientific advice. The company’s second program, OLN102, is a TSHR/IGF-1R bispecific antibody discovered with VelaVigo and is expected to enter clinical development in 2026 for thyroid eye disease and Graves’ disease. Ollin positions its candidates as potentially best-in-disease therapies and is using recent financing to fund registrational studies and further clinical development.

Total raised

$430M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2026